A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Endometrial Cancer
  • Age: Between 18 years - 99 years
  • Gender: Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) patients who have been diagnosed with EC, which can include different types of cancer such as endometrioid, serous, undifferentiated, and carcinosarcoma
    2. 2) TP53 gene which will be evaluated on the tumor using a technique called NGS to determine if it has any mutations which is required for participation.
    3. 3) completed at least 12 weeks of platinum-based therapy, which is a type of chemotherapy treatment, and achieved a confirmed partial or complete response by imaging

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) patients with certain types of uterine sarcomas, or clear cell or small cell carcinoma with neuroendocrine differentiation
    2. 2) patients who have received a blood or platelet transfusion within 2 weeks prior to Cycle 1 Day 1
    3. 3) patients who are receiving concurrent systemic steroid therapy at a dose higher than the physiologic dose



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.